This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
159
SPARC Site 1
Hanover, Germany
Change in Total Nasal Symptom Score (TNSS)
Time frame: Baseline and 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.